Rib-X Pharmaceuticals, Inc. Receives Award from National Institute of Allergy And Infectious Diseases (NIAID) to Develop Antibiotic Treatment for Gonorrhea

NEW HAVEN, Conn., Sept. 14 /PRNewswire/ -- Rib-X Pharmaceuticals, Inc., a company focused on the discovery, development and commercialization of novel drugs for the treatment of multi-antibiotic resistant infections, today announced that it intends to enter into a Clinical Trials Agreement with the U.S. National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), an agency of the United States Department of Health and Human Services. The purpose of this agreement is to advance the clinical development of an oral formulation of Rib-X's novel fluoroquinolone delafloxacin, in the treatment of Neisseria gonorrhoeae.

This agreement with the NIAID will further support the broad clinical potential for our lead compound, delafloxacin, which has already demonstrated potent activity against a variety of resistant bacteria and has successfully completed three Phase 2 trials," said Susan Froshauer, PhD, President and CEO of Rib-X Pharmaceuticals. "In recent years, gonococcal infections have become increasingly resistant to available antibiotic treatments and we look forward to collaborating with the team at NIAID in the coming months to evaluate possible alternative therapeutic options for such infections."

About Rib-X Pharmaceuticals, Inc.

For more information on the Rib-X mission and the pipeline, please visit the Company website at www.rib-x.com.

Rib-X Pharmaceuticals, Inc.



Back to news